Summary by Futu AI
KOZAI PHARMACEUTICALS ANNOUNCED THAT DUE TO THE FAILURE OF THE PARTIES TO REACH AN AUDIT TIMETABLE FOR 2023 WITH THE ACCOUNTING FIRM OF ROBINGHAM SUNGAO, IT HAS RESIGNED AS AUDITOR OF THE COMPANY ON 12 JANUARY 2024. Prior to his tenure, the U.S. subsidiary received an FDA request to suspend some clinical trials, citing a number of problems with the company, including credit card usage controls, employee late stays, and document regulatory discrepancies, among others. Kozai Pharmaceuticals has conducted internal reviews and measures on these issues. The Board of Directors subsequently decided to appoint EY Accountants as the new Auditor for a term of office until the end of the next Annual General Meeting. The Company expresses its gratitude for its past service and welcomes the appointment of new auditors at EY.